Professor Sander van Deventer appointed to Supervisory Board of AMT
CFO Piers Morgan appointed to Management Board
Amsterdam Molecular Therapeutics announced that, at the Annual General Meeting (AGM) of the Company Professor Sander van Deventer has been appointed to the Supervisory Board.
Professor van Deventer is one of AMT’s co-founders. He was Professor and Head of the Department of Experimental Medicine, Chairman at the Department of Gastroenterology of the AMC from 2002 to 2004, and subsequently Professor of Experimental Medicine at the University of Amsterdam Medical School until 2008. He has over 15 years experience in biotechnology product development. He is the author of more than 350 scientific articles in peer-reviewed journals and serves as an advisor to regulatory authorities including the EMA and FDA.
Professor van Deventer served on the Management Board of AMT as Chief Scientific Officer until February 2009, and temporarily also as Chief Executive Officer from February - October 2009. He currently chairs the Scientific Advisory Board of AMT. He is also a partner of Forbion Capital, a shareholder in the Company, and Professor of Translational Gastroenterology at the Leiden University Medical Center (LUMC).
As a result of Professor van Deventer’s previous position as a member of the Management Board, among others, he is not independent within the meaning of provision III.2.2 of the Dutch Corporate Governance Code.
Also at the Annual General Meeting Mr Piers Morgan, CFO, was appointed to the Management Board and Mr Alexander Ribbink retired as a member of the Supervisory Board. All resolutions proposed to the Annual General Meeting, as set out in the Notice of General Meeting dated April 12, 2010, were approved unanimously.
Other news from the department people
